Form 4: Ionis Pharma Exec Sells Shares After Option Exercise
Insider Transaction Report
Shannon L. Devers, EVP, Chief Human Resources Officer at Ionis Pharmaceuticals, reported exercising stock options and selling shares, including a tax-related sale.
Summary
- Shannon L. Devers, EVP, Chief Human Resources Officer, reported multiple transactions involving Ionis Pharmaceuticals Inc. common stock.
- On October 15, 2025, Devers exercised Non-Qualified Stock Options to acquire 6,000 shares at $48.51 per share.
- Concurrently on October 15, 2025, Devers sold 6,000 shares at a weighted average price of $72.9423, as part of a Rule 10b5-1 trading plan adopted on September 3, 2024.
- Also on October 15, 2025, 2,820 shares were acquired through the vesting of Restricted Stock Units (RSUs).
- On October 16, 2025, an additional 1,263 shares were sold at $73.6213 to cover tax withholding obligations related to the RSU vesting.
- Following these transactions, Devers beneficially owns 17,494 shares of common stock and 60,406 Restricted Stock Units.
Sentiment
Score: 6
Explanation: The filing reports routine insider transactions including the exercise of stock options, vesting of Restricted Stock Units, and subsequent sales of shares. One sale was pre-planned under a Rule 10b5-1 plan, and another was for tax withholding, which are common and generally not indicative of negative sentiment. The insider realized a profit on the option exercise and subsequent sale.
Positives
- The reporting person realized a gain by selling shares at $72.9423 and $73.6213 after exercising options at $48.51.
- The sale was partially conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a structured approach to managing equity.
Negatives
- The reporting person sold a total of 7,263 shares over two days, which, while routine for tax and planned sales, represents a reduction in direct share ownership.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: May observe insider selling, but the planned and tax-related nature of the sales reduces concerns about management's confidence in the company's future. The insider is realizing gains from equity compensation.
Key Dates
| Date | Description |
|---|---|
| 04/05/2021 | Date Non-Qualified Stock Option became exercisable. |
| 09/03/2024 | Rule 10b5-1 Trading Plan adopted by the reporting person. |
| 10/15/2025 | Exercise of Non-Qualified Stock Options, sale of shares under 10b5-1 plan, and vesting of Restricted Stock Units. |
| 10/16/2025 | Sale of shares to cover tax withholding obligations. |
| 04/04/2027 | Expiration date of Non-Qualified Stock Option. |
Keywords
Ionis Pharmaceuticals, IONS, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, Shannon L. Devers, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.